Trial Profile
A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Temozolomide (Primary)
- Indications Carcinoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2021 Status changed from active, no longer recruiting to completed.
- 14 Feb 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 14 Feb 2020 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2021.